论文部分内容阅读
目的研究VEGF配体及其受体在结肠癌发生、发展、转移中的作用,探讨VEGF家族与结肠癌各个时期病理特征的关系。方法在肿瘤标本,癌旁及正常组织标本中,用半定量RT-PCR方法,测定各种标本中VEGF各配体及VEGF受体表达,以研究它们在结肠癌进程中的作用。同时用免疫组化方法,对上述因子进行研究。结果 (1)与正常组织相比,VEGF-A、VEGF-C在肿瘤组织中显著升高(P<0．01);VEGF-B在肿瘤和正常组织中表达相近,而VEGF-D在肿瘤组织中显著降低;(2)VEGF-A、VEGF-B、VEGF-C在有淋巴结转移的肿瘤中明显升高(P<0．01);VEGF-D在有淋巴结转移的肿瘤中下降,但没有统计学差异。(3)VEGFR-1与Duke’s分期,淋巴结转移显著相关(P<0．01);VEGFR-2与淋巴结转移显著相关(P<0．01);VEGFR-3与临床病理特征均不相关;VEGFR-1在肿瘤组织比正常组织升高(P<0．01),但VEGFR-2和VEGFR-3表达在肿瘤进程中没有显著升高。结论 VEGF-A、VEGF-B与结肠癌早期发展过程相关,VEGF-C、VEGFR-1与结肠癌进展过程相关,并和VEGF-D、VEGFR-2共同参与转移过程。
Objective To study the role of VEGF ligand and its receptor in the development, progression and metastasis of colon cancer and to explore the relationship between the VEGF family and the pathological features of colon cancer at various stages. Methods The expressions of VEGF ligand and VEGF receptor in various specimens were determined by semi-quantitative RT-PCR in tumor specimens, adjacent normal tissues and normal tissues to investigate their role in the progression of colon cancer. At the same time by immunohistochemistry, the above factors were studied. Results (1) Compared with normal tissues, VEGF-A and VEGF-C were significantly increased in tumor tissues (P <0.01); VEGF-B was similar in tumors and normal tissues, while VEGF- (2) VEGF-A, VEGF-B and VEGF-C were significantly increased in tumors with lymph node metastasis (P <0.01); VEGF-D was decreased in tumors with lymph node metastasis No statistical difference. VEGFR-1 was significantly associated with Duke’s stage and lymph node metastasis (P <0.01); VEGFR-2 was significantly correlated with lymph node metastasis (P <0.01); VEGFR-3 was not associated with clinicopathological features; VEGFR- -1 was higher than that in normal tissue (P <0.01), but the expression of VEGFR-2 and VEGFR-3 was not significantly increased in tumor progression. Conclusions VEGF-A and VEGF-B are related to the early development of colon cancer. VEGF-C and VEGFR-1 are associated with the progression of colon cancer and are involved in the process of metastasis with VEGF-D and VEGFR-2.